Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) - Oct 31, 2023 - "Through the remainder of 2023 and 2024, the Company plans to accomplish the following key business objectives: (i) Complete enrollment in the Phase 2 ReSPECT-GBM trial and finalize pivotal design with FDA; (ii) Complete enrollment in the Phase 1 ReSPECT-LM trial and begin phase 2 trial; (iii) Complete internal implementation of the CNSide cerebrospinal fluid (CSF)-based biomarker and tumor cell capture and enumeration assay being utilized in the ReSPECT-LM clinical trial; (iv) Obtain FDA IND approval and initiate the Phase 1 ReSPECT-PBC trial for pediatric patients with ependymoma and high-grade glioma at the Lurie Children's Hospital in Chicago; (v) Publish ReSPECT-GBM Phase 1 data in a peer-reviewed publication."
Biomarker • Enrollment status • IND • P1 data • Ependymoma • Glioblastoma
|